1Y Target$39.77Near-term target
5Y Target$59.25Compound horizon
10Y Target$154.19Long-dated conviction
FCF-$166mTTM · 03/26FFCF is negative (-$166m) — cash-burning phase; acceptable only for pre-profit spec names · TTM computed from 4 most-recent quarters (TTM · 03/26).
Rev+52.9%TTM YoYARevenue +52.9% — hypergrowth, top decile · TTM YoY from trailing-4-quarter revenue sum vs prior 4 quarters.
D/E0.00AD/E 0.00 — essentially debt-free, pristine balance sheet
P/S9.4xB-P/S 9.4x — moderate premium for growth
PEG—proxy—PEG not meaningful — earnings growth negative or data unavailable · PEG proxy: P/E ÷ revenue growth % (true PEG requires forward EPS estimates, not in Finnhub free tier).
Why now
Biotechnology · market cap $1.4b. 9% off the 52-week high of $32.37. Revenue growing +53% — in hypergrowth territory.
Moat
Pharma moat is patent runway + pipeline depth — a single approved molecule funds the next generation of bets. Late-stage trials carry binary readouts that swing valuation 30%+.
Risk
Free cash flow is negative (-$166m) — capital raises or debt issuance likely required; dilution / leverage risk. Currently unprofitable (margin -94.8%) — path to GAAP profitability is the core thesis risk. Beta 1.59 implies above-market volatility — position-size to the drawdowns this name will produce in a market correction, not to its bull-case return.
Horizon
1-3 yr $39.77 (structural (no analyst coverage)) — catalyst-driven; binary events dominate. 5 yr $59.25 — requires the platform / technology to reach commercial scale. 10 yr $154.19 — return distribution heavily skewed.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See
terms and
methodology for full disclosures.